

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Fingolimod for the treatment of relapsing-remitting multiple sclerosis

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Novartis (fingolimod) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Black Health Agency • Brain and Spine Foundation • Chinese National Healthy Living Centre • Counsel and Care • Equalities National Council • Leonard Cheshire Disability • Multiple Sclerosis National Therapy Centres • Multiple Sclerosis Resource Centre • Multiple Sclerosis Trust • Multiple Sclerosis Society • Muslim Council of Great Britain • Muslim Health Network • Neurological Alliance • Neurosupport • Royal Association for Disability & Rehabilitation (RADAR) • South Asian Health Foundation • Specialised Healthcare Alliance • Sue Ryder Care <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • British Association for Services to the Elderly • British Geriatrics Society • British Neuropathological Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • Neurological Alliance of Scotland • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • NHS Quality Improvement Scotland • Public Health Wales NHS Trust • Scottish Medicines Consortium • Wales Neurological Alliance <p><u>Comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> • Bayer (interferon beta-1b) • Biogen Idec (interferon beta-1a, natalizumab) • Elan Pharma International (natalizumab) • Merk Serono (interferon beta-1a) • Sanofi-Aventis (glatiramer acetate) • Teva (glatiramer acetate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Neurological Research Trust

Appendix B

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Society of Rehabilitative Medicine • Institute of Neurology • Primary Care Neurology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine – Intellectual Disabilities Forum • United Kingdom Clinical Pharmacy Association • UK MS Specialist Nurses Association (MSSSNA) <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS North Yorkshire and York • NHS South Staffordshire • Welsh Assembly Government 	<ul style="list-style-type: none"> • MRC Clinical Trials Unit • National Institute for Health Research • Policy Research Institute on Ageing and Ethnicity • Research Institute for the Care of Older People <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • Aberdeen HTA Group • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Chronic Conditions <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • None

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.